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1. Introduction 
 
1.1. Neuroinflammatory processes and microglial 
activation 
Historically the Roman Celsius is considered the first to have defined 
the four cardinal signs that characterized inflammation: “rubor et 
tumor cum calore et dolore” (redness and swelling with heat and 
pain). This definition of inflammation is still in use, however in recent 
years new models of inflammation have been developed.  They are 
based on molecular phenomena, in fact the term “inflammation” refers 
to a generic multicellular process, characterized by changes in local 
vasculature, activation of resident immune competent cells, infiltration 
of mobile cells of the immune system and cytokine production [1]. 
Neuroinflammation (NI) is the inflammation of the nervous system, 
observed in disease of the Central Nervous System (CNS). All these 
neuropathologies are characterized by a series of complex events 
involving microglia, astrocytes and infiltrating peripheral immune 
cells, important in neurodegenerative processes and tissue repair [2]. 
NI typically occurs when blood–brain barrier (BBB) is not able to stop 
biological insults, but it may also occur in acute noninfectious 
neuropathologies like stroke or chronic diseases such as multiple 
sclerosis, neurodegenerative and psychiatric disorders [3]. Acute 
lesions usually induce an important neuroinflammatory response 
leading to local changes of blood flow and vascular permeability, 
alteration of the BBB, infiltration of peripheral macrophages and 
activation of resident microglia [4].  Moreover, the pathogenesis and 
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progression of chronic neurodegenerative diseases are characterized 
by an important inflammatory response, primarily mediated by 
specific cells as microglia and astrocytes [5]. CNS presents biological 
links at many levels and it is highly integrated with the immune 
system [6]. The first evidence that support the connection between 
CNS and immune system is the presence of hypothalamus–pituitary–
adrenal (HPA) axis, an immune-neuro-endocrine circuit characterized 
by interconnection involving peripheral immune mechanisms and 
endocrine responses under brain control [7]. An important event is the 
release of regulatory signaling factors as corticosteroids and 
proinflammatory cytokines like tumor necrosis factor-alpha (TNF-α) 
and interleukin 6 (IL-6), that not only influence the HPA axis–
mediated glucocorticoid feedback loop, but also they are involved in 
the regulation of a variety of neuronal circuits such as 
thermoregulation, food intake and other behaviors related to diseases. 
These pro-inflammatory cytokines, generated in the periphery, 
communicate with the brain, to initiate cytokine synthesis in the CNS 
[8]. 
In fact cytokines secreted by immune cells in the periphery, cannot 
diffuse across an intact blood–brain barrier (BBB) although there is 
evidence that they can diffuse from the circulation to BBB deficient 
brain areas, like the choroid plexus and circumventricular organs or 
can be carried by endothelial cell transporter into the CNS [9]. 
Alternatively, to transmit a stimulatory signal to the CNS, blood-borne 
cytokines have to activate BBB endothelial cells and consequently 
neurons, through the involvement of soluble factors and activation of 
glial cells [10].  
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Glial cells constitute a large percentage of cells in the nervous system. 
Glia has an active role in brain function and is involved in every type 
of neurodegenerative disease, in particular the main actors of the 
innate immune response of the CNS are microglial cells that represent 
approximately 10% of the entire population of the brain. Microglia are 
myeloid cells of the CNS that are derived from early embryonic 
erythro-myeloid progenitor cells and have migrated into the 
developing nervous tissue, where they begin the maturation process 
into brain-resident microglial cells. Microglia are involved in various 
developmental processes such as cerebral tissue homeostasis, 
apoptosis, axonal growth and guidance, regulation of embryonic 
cortical precursor, cell development, neuronal differentiation, 
angiogenesis, phagocytosis of extracellular debris, secretion of 
inflammatory mediators and production of factors important for 
astrocytes, another type of glial cells with support functions [11]. 
Under physiological conditions, microglia show a noninflammatory 
phenotype, but after various environmental and noxious stimuli, can 
change from a resting to an activated state. The processes of microglia 
activation is associated with proliferation and transformation into 
reactive microglia with different response phenotypes. In healthy 
brain, microglial cells are quiescent and non-motile cells, 
characterized by a small cell body with fine, branched processes and 
low expression of surface antigens [12]. Under pathological 
conditions such as infectious diseases, stroke or neurodegenerative 
processes, microglia become activated through a rapid transformation 
into a phagocytic state. During this transition microglial cells, with a 
larger cell body and shorter cellular processes, become motile and use 
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amoeboid-like movements, to migrate to and within the lesion site 
(Fig. 1).  
 
 
 
Fig. 1. Illustration of microglial phenotypic plasticity in CNS (Graeber et al. 2011) [1].  
 
 
Activated microglia not only change their phenotype and migrate to 
the site of damage, but also clear cellular debris by phagocytosis and 
release a large amounts of soluble factors that include pro- and anti-
inflammatory cytokines and chemokines, oxidative stress-inducing 
factors like nitric oxide (NO) as well as growth factors and 
immunomodulatory factors and reactive oxygen species (ROS) [13]. 
In particular, the simplest manner to describe microglial activation is 
to use the similarity with two macrophage types described in 
peripheral inflammation. Depending on the mode of activation, 
surveying microglia may come into two phenotypes: the 
proinflammatory “M1” phenotype, activated by lipopolysaccharides 
and interferon-γ, corresponds to classical macrophage activation, 
while the anti-inflammatory “M2” phenotype is activated by 
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interleukin (IL)-4 and IL-13 through the “alternative” pathway of 
macrophage activation. M1-type microglia produce tumor necrosis 
factor-α, IL-1β, IL-6, nitric oxide, superoxide, hydrogen peroxide, and 
matrix metalloproteinases. The M1 microglia phenotype actively 
participates in host defense against pathogens and tumor cells, but also 
triggers damage to healthy neurons. In contrast, the anti-inflammatory 
M2 microglia phenotype expresses IL-10 and arginase-1 and promotes 
tissue remodeling/repair and angiogenesis [13] (Fig. 2).  
 
 
 
Fig. 2. Macrophages/microglia can be classified in a simplified manner into two subsets of 
phenotypes and effector functions depending on the activation pathway (Czeh et al. 2011) [13]. 
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1.2. Neuroinflammation in mouse model of human disease 
 
There is important evidence in animal models that NI is involved in 
the most part of neurological disorders, making NI a potential target to 
diagnose diseases, to monitor the progression and to test new therapies 
[14]. An increasing number of interventional or transgenic rodent 
models (rat, mouse) of acute or chronic NI, mimicking different 
human neuropathologies, have become available and extensively 
characterized [15-16].  
Although none of these animal models shows all aspects of human 
diseases, they might provide valuable information on basic molecular 
processes of NI that are of crucial importance for the development of 
novel therapeutic strategies. In particular, laboratory mice are not 
expensive, easy to handle and to maintain in a research facility with 
respect to other animal species. If compared with man, mice show 
adequate morphogenetic homology, and are important surrogate 
models of genetic and even of non-genetic disorders. A perfect animal 
model, like mouse, should reflect all aspects of the human disease, as 
symptoms, lesions and causes of the disease. It is important to 
evaluate continuously the models for their match with the human 
disease and revaluate them in light of new findings in human patients. 
Therefore, the use of animal models has been proven to be a useful 
tool to clarify underlying molecular mechanisms of neurodegenerative 
disorders and to discover potential therapeutic and reparative 
strategies [16]. Among neuroinflammatory pathologies, including 
stroke, Alzheimer’s disease and Parkinson’s disease, this work 
focused on a mouse model of chronic degeneration in amyotrophic 
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lateral sclerosis (ALS) and a mouse model of acute inflammation in 
multiple sclerosis (MS). 
 
1.2.1. Amyotrophic lateral sclerosis – SOD1 G93A mouse model 
 
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease, 
characterized by a progressive loss of motor neurons (MN) in 
brainstem nuclei, motor cortex and spinal cord. Degeneration of MN 
results in muscle weakness and spasticity, and respiratory failure, 
leading to death within approximately 3 – 5 years of symptom onset 
[17]. Although ALS was first described more than 140 years ago by 
Charcot in 1874, most major advances for a better knowledge of the 
pathophysiology of the disease have occurred in the last 2 decades 
[18]. Recent progresses in knowledge of various genetic mutations 
that causes ALS, such as mutations in superoxide dismutase 1 
(SOD1), have laid the basis of the generation of a number of new 
rodent models of disease helping to the development of new 
diagnostic and therapeutic strategies. SOD1 transgenic mouse has 
resulted the model that best describes ALS phenotype [19]. Most 
cases of human ALS are sporadic, but approximately 20 % of familial 
ALS and 5 % of apparently sporadic disease are associated with the 
gene encoding the enzyme Cu2+/Zn2+ superoxide dismutase (SOD1) 
[20]. SOD1 is the cytosolic Cu/Zn-binding isoform of SOD that 
catalyzes the detoxification of superoxide radical (O2¯) to convert it to 
hydrogen peroxide (H2O2), when there is a reduction or an increase in 
SOD enzyme, activity oxidative stress occurs [21]. 
The point mutation in the gene encoding SOD1 was identified in 1993 
[22] and since then, ALS research has advanced substantially by 
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studying rodent models and exploring how mutations in SOD might 
selectively cause motor neuron degeneration. Several SOD1 mutants 
of transgenic mice have been generated [23] and the G93A and G37R 
mutations are the most commonly used to generate transgenic ALS 
models, respectively with the substitution of arginine for glycine at 
position 37 and the substitution of glycine for alanine at position 93 
[24-25]. 
These mice exhibit the ALS-like clinical features that are transmitted 
in an autosomal dominant way [26]. The progressive motor neuron 
degeneration is characterized by hind limb weakness and tremulous 
movements as initial symptoms, followed by more severe symptoms 
such as progressive motor paralysis and disability of gait, eating and 
drinking, and death within some weeks. The mechanisms 
characterizing neurodegeneration in ALS are multifactorial and 
involve a complex interaction between molecular and genetic 
pathways. Neuroinflammation and activated microglia are 
neuropathological features of ALS and play a significant role in MN 
degeneration and disease progression [27]. Studies on human ex-vivo 
tissues have shown astrocytosis and microgliosis in motor cortex, 
motor nuclei of the brainstem, anterior horn of the spinal cord, and 
corticospinal tract [28]. Interestingly, the transgenic mouse 
overexpressing a mutant form of human SOD1, also displays ex-vivo 
similar inflammatory responses to those seen in ALS patients, 
including activated microglia, astrogliosis and infiltrating 
lymphocytes also with  MN injury in brainstem and  spinal cord [29]. 
Therefore, mouse models of ALS, like SOD1-G93A, is a good model 
that give a useful and relevant tool for investigating 
neuroinflammation.  
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1.2.2. Experimental autoimmune encephalomyelitis – EAE mouse 
model 
 
Multiple sclerosis (MS) is an autoimmune, neuroinflammatory and 
neurodegenerative disease of CNS. The pathological hallmarks are 
focal demyelinated plaques within the CNS showing different degree 
of inflammation, gliosis and axonal damage depending the timing and 
clinical phenotype [2]. Although MS is primarily a disease affecting 
the white matter, recent studies suggest that demyelinated lesions 
might be found in the cortical gray matter of MS patients [30]. The NI 
response in MS is mediated by peripheral lymphocytes and activated 
monocytes and as well as by innate immune cells, in particular 
microglia may contribute both to degeneration and, as recently 
suggested, to tissue repair [31]. The sclerotic plaques are 
characterized by an inflammatory reaction involving T cells, B cells 
and extensive macrophage/microglia activation, demyelination, 
remyelination and a concomitant neuronal and axonal degeneration 
[32]. Migration of aggressive myelin-reactive T cells into the CNS is 
followed by microglia activation and macrophage invasion with 
consequent oligodendrocyte destruction. Damage to oligodendrocytes 
leads eventually to damage of myelin sheaths, due to lack of myelin 
repair. The breakdown of myelin sheaths initiates a more severe wave 
of T-cell infiltration, which is accompanied by B-cells infiltration 
[33]. Acute lesions are characterized by inflammatory cell infiltration, 
myelin sheath debris and BBB damage, instead chronic lesions present 
low levels of inflammation and absence of active myelin breakdown 
[34-35]. Experimental autoimmune encephalomyelitis (EAE) is the 
most commonly used preclinical model that reproduces the key 
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pathological features of human MS [36] and is the most widely 
studied in the research field. The origins of this animal model go back 
to the 1920s, when an inflammation in rabbits spinal cord was induced 
by inoculation with human spinal cord [37]. After that, one of the first 
experiment was studied in the 1930s, when monkeys were immunized 
with repeated injections of rabbit brain extracts [38] and afterwards 
with the addition of Freund’s adjuvant [39]. Only some years later, 
the immunization was complemented by pertussis toxin [40]. 
Although EAE model has been induced in various animal species, 
rodents are the most extensively used in biomedical research, and in 
the last decades, they have been widely characterized, using different 
strains to reproduce MS after immunization with myelin proteins or 
peptides [41]. The most relevant immunogens are derived from self-
CNS proteins or peptides, usually parenteral administered in adjuvants 
such as complete Freund’s adjuvant and pertussis toxin.  
Depending of the immunizing neuroantigen and the rodent strain used, 
different clinical phenotypes of MS and histological/ 
neuroinflammatory changes can be obtained: proteolipid protein 
peptide (PLP139-151) induced a relapsing remitting disease course in 
SJL mice; myelin basic protein (MBP) induced a non-demyelinating 
acute monophasic disease in PL/J mice; chronic-progressive models of 
myelin oligodendrocyte glycoprotein (MOG35-55) peptide induced 
disease in C57/BL6 mice [36].   
Stereotactic intrastriatal injection of heat-killed bacillus Calmette-
Guérin (BCG) and subsequent activation using an intradermal 
injection of BCG in Lewis rat induced a chronic focal EAE [42]. In 
addition, toxin-induced EAE (cuprizone and lysophospho-lecithin) 
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and intracerebral virus inoculation–induced EAE are other available 
mouse models of MS [43].  
Clinical signs of rodents EAE models are characterized by a weight 
loss accompanied by an ascending paralysis starting from the tail and 
hind legs. Many factors can influence the onset and progression of 
disease, as age, gender, season at immunization [44], genetics factor 
[45] and type of antigen [47].The EAE model used for this study is 
characterized by immunization with PLP139-151 peptide in complete 
Freund’s adjuvant in SJL female mice. This model develops first 
symptoms between 11-12 days after immunization followed by a 
complete or partial recovery within 7-10 days. EAE animals showed a 
progressive paralysis starting from caudal to rostral areas of CNS. 
 
1.3. Translocator protein TSPO and its role in 
neuroinflammation 
 
The peripheral-type benzodiazepine receptor (PBR) was identified in 
1977, when diazepam-binding sites were characterized in peripheral 
tissues. So the expression “peripheral type” benzodiazepine receptors 
allowed to distinguish them from the central benzodiazepine receptor, 
which is part of the GABAA receptor complex. Although the name 
PBR is widely accepted in the scientific community, in 2006 
Papadopoulos and colleagues reached a consensus on a new name: 
translocator protein (18 kDa) (TSPO), which applies to the protein 
regardless of its localization [47]. TSPO is a component of the 
mitochondrial permeability transition pore (MPTP) a multimeric 140-
200-kDa proteic complex that consists of different protein: the 32 kDa 
voltage-dependent anion channel (VDAC) and the 30-kDa adenine 
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nucleotide transporter (ANT). The 18-kDa protein, with five 
transmembrane domains, facilitates the passage of lipophilic 
molecules across the cellular intermembrane space. There are two 
other TSPO associated proteins, PBR-associated protein 1 (PRAX-1) 
and PBR and protein kinase A associated protein 7 (PAP7) that 
facilitate complex formation [48] (Fig. 3).  
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Fig. 3.  Structure and role of TSPO for cholesterol transport into mitochondria. TSPO interacts 
with VDAC and ANT to form a complex that is located preferentially in outer-inner mitochondrial 
membrane contact sites. The TSPO-associated proteins PRAX-1 and PAP7 could facilitate 
complex formation or cholesterol targeting to TSPO (Papadopoulos et al. 2006) [47]. 
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TSPO participates in a lot of cellular function as cholesterol binding 
followed by cholesterol transport, important in steroid biosynthesis; 
protein import, fundamental for membrane biogenesis; porphyrin 
binding and transport, which is involved in heme biosynthesis, but 
also permeability transition pore opening, regulation of mitochondrial 
function, cell proliferation, differentiation and apoptosis. TSPO is 
widely expressed in many peripheral tissues, such as adrenals, 
kidneys, lung and spleen. It is also found in other region including 
heart, liver, testis, blood cells. Under normal condition, TSPO is 
expressed at very low levels in the brain, where is mainly localized in 
glial cells, including astrocytes and infiltrating macrophages, and at 
low levels in neurons. In contrast, TSPO expression increases 
following a neuroinflammatory event and a neuronal injury, as stroke, 
Parkinson's disease, Alzheimer's disease, multiple sclerosis, 
Huntington's disease and amyotrophic lateral sclerosis [49]. 
The high level of TSPO expression in glial cells as well as the 
increased proliferation of microglia in gliosis, suggests that the 
expression of TSPO could serve as a marker to monitor the state and 
progression of brain NI following brain injury [50-51] (Fig 4). 
Interestingly, TSPO might also be a therapeutical target: modulation 
of TSPO expression might be also implicated in neuronal survival and 
regeneration [52].  
 
 
 
 
 
 
15 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4. TSPO are overexpressed by activated microglia (Banati et al. 2002) [51].  
 
 
1.4. PET and TSPO in animal models 
 
Molecular imaging (MI) using Positron Emission Tomography (PET) 
may be a useful tool for in vivo study of NI in animal models. The 
combined use of NI rodent models and microPET is an emerging 
approach that contributes to the characterization and validation of new 
radioligands especially when combined with immunohistochemistry, 
allowing complementary characterization of histopathological changes 
underlying in vivo imaging. In additions, it allows the monitoring of 
the spatio-temporal dynamic of the neuroinflammatory changes 
occurring in neurological disorders since the earliest/asymptomatic 
stages, the evaluation of their relationship with disease progression 
TSPO 
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and the investigation of the effects of potential treatments. Activated 
microglia and astrocytes are of particular interest for radiolabeled PET 
probes, because they represent the innate CNS-resident immune cells, 
are involved in both neuroprotective and neurodegenerative processes 
following brain damage and are potential target for new anti-
inflammatory therapies. In recent years, there has been an increase 
effort in the development of radioligands targeting TSPO for in vivo 
PET imaging of glial activation in human and animal studies [53].  
 
 
1.4.1. Principles of PET/CT  
Positron emission tomography (PET) is a sensitive and specific 
medical technique for imaging molecular pathways in vivo and in a 
non-invasive way. It is based on the administration of compounds 
labeled with short-lived positron-emitting radionuclides. Typical 
isotopes used as radionuclides in PET are fluorine-18, carbon-11, 
nitrogen-13 and oxygen-15. These radionuclides are incorporated into 
biological compounds that play a specific role in different living 
organs. The spontaneous decay of a positron emitter produces a 
positron, which travels a short distance to finally react with one 
electron of a surrounding atom. This process is called annihilation; as 
a result, two gamma photons are emitted (511 keV each, emitted at 
180º C to each other). The generation of these gamma rays is the basis 
of positron emission tomography. When a tracer containing a positron 
emitter is administered to an organism, the high-energy gamma rays 
produced, which have a high penetration power, escape from the body 
and are detected by an external ring of detectors as a coincident event. 
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The detection of hundreds of thousands of such coincident events 
permits the reconstruction of an image that contains information about 
the distribution of the radiolabeled tracer within the organism [54]. 
Integrated PET with CT in a single unit provides complementary 
informations and allows fusing of the anatomical data of CT with the 
functional information of PET (Fig. 5).  
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Fig 5. Principles of Positron Emission Tomography (Venneti et al, 2013)  
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1.4.2. TSPO PET radioligands  
 
PK11195 [1-(2-chlorophenyl)-N-methyl-N-(1-methyl-propyl)-3-
isoquinoline carboxamide] is the first non-benzodiazepine and 
selective TSPO ligand developed and labeled with carbon-11. This 
TSPO antagonist, discovered in 1984 [55], has been the most 
commonly used TSPO radioligand for in vivo PET imaging or 
autoradiography [56]. However, numerous limitations have been 
pointed out: low brain uptake, high level of non-specific binding, poor 
signal-to-noise ratio, that complicates its quantification, extensive 
binding to plasma proteins, which complicate quantitative analysis of 
the receptor density and in addition the short half-life of carbon-11 
(20.38 min) [57]. All these characteristic limit its accuracy, 
dissemination and wide preclinical and clinical use [58]. 
Over last two decades, efforts have been undertaken to develop 
several new TSPO-specific radiotracers, labeled with carbon-11 but 
also with the longer lived positron-emitter fluorine-18 (109.8 min) in 
an attempt to avoid some of the limitations observed with 
[11C]PK11195. Therefore, extensive research has led to the 
development of new TSPO tracer like [11C]DAA1106, 
[18F]FEDAA1106, [11C]PBR28 that have been described and 
reported to display in vivo properties in rodents brains. 
[11C]DAA1106 and [18F]FEDAA1106 have also been shown to 
display highly specific in vivo uptake in primate brains. Furthermore, 
[18F]FEDAA1106 was recently evaluated in human PET studies [59].  
In the last decade, a series of TSPO-specific pyrazolopyrimidine 
ligands were synthesized and in particular one of these tracers, N,N-
diethyl-2-(2-(4-methoxyphenyl)-5,7-dimethylpyrazolo [1,5-
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a]pyrimidin-3-yl) acetamide (DPA-713), was labeled with 11C. PET 
studies showed that [11C]DPA-713 selectively and specifically bound 
the TSPO in normal baboon brains [60]. All these encouraging results 
suggested to synthesize a derivative of DPA-713, the 
pyrazolo[1,5]pyrimidine DPA-714, labeled with fluorine 18. Fluorine 
18 has physical characteristic more favorable than carbon 11, like a 
longer half-life and lower positron energy. This allows the wide 
distribution of the radiotracer to sites different from that of synthesis 
and favors longer scanning time. 
 
 
1.5. [18F]DPA-714 a new suitable radiotracer for PET 
studies 
 
 
N,N-diethyl-2-(2-(4-(2-fluoroethoxy)phenyl)-5,7-
dimethylpyrazolo[1,5-a]pyrimidin-3-yl)acetamide (DPA-714), a 
TSPO agonist, was developed and labeled with fluorine 18 (half-life 
of 109.8 min). In 2008, James ML. et al. studied and evaluated this 
radiotracer ex-vivo in a neuroinflammatory rat model and in vivo in a 
healthy baboon using PET. Ex-vivo biodistribution studies in rats 
showed highest accumulation of [18F]DPA-714 in the heart and 
adrenal glands, with only minimal accumulation in the bone, liver, and 
muscle. Pretreatment with DPA-714 (1 mg/kg) resulted in inhibition 
of radioligand uptake in the heart and partially in the adrenal glands. 
An elevated uptake was observed in the ipsilateral striatum, as 
compared to contralateral striatum that was specific since it was 
inhibited by preinjection of a large dose of unlabeled PK11195, DPA-
21 
 
714 and DPA-713. In vivo biodistribution and specificity of 
[18F]DPA-714 were also characterized in a normal male baboon with 
PET.  In a base-line study, the time-activity curves of the whole brain 
[18F]DPA-714 uptake showed a fast uptake reaching the maximum at 
10 minutes after the radiotracer injection followed by a slow wash-out 
during 60 minutes. Pretreatment with PK11195, five minutes before 
radioligand injection, resulted in an initial increase of [18F]DPA-714 
uptake, followed by a rapid decrease. Displacement with DPA-714 
injected 20 minutes after radiotracer, led to a sharp peak followed by a 
complete washout of [18F]DPA-714. In extracerebral organs, the 
[18F]DPA-714 uptake was higher in the heart, kidneys, adrenal 
glands, and salivary glands. The injection of nonlabeled DPA-714, 20 
minutes after radioligand administration, displaced [18F]DPA-714 
binding in these peripheral regions. These results suggested that 
[18F]DPA-714 is a high-affinity radioligand specific for TSPO and its 
ability to bind to TSPO with high specificity, make this ligand an 
attractive tool for evaluating TSPO neuroinflammatory processes 
[59]. Subsequent in vivo studies with microPET in rat models of NI 
confirmed the increased binding and the specificity of [18F]DPA-714 
in the inflammatory areas [61-62].  Moreover these studies compared, 
in the same model, the sensitivity and the specificity of [18F]DPA-
714 to those of other radioligands such as [11C]DPA-713 and 
[11C]PK11195. The results suggested that in vivo, [18F]DPA-714 
performed better than [11C]DPA-713 and [11C]PK11195, with the 
highest ratio of ipsilateral to contralateral uptake and the highest 
binding potential in a model of unilateral acute intrastriatal lesion 
[61]. Also Doorduin et al. compared [18F]DPA-714, [11C]DPA-713 
and [11C]PK11195 in a rat model of herpes encephalitis and found no 
22 
 
significant difference in sensitivity between the 2 carbon-11-labeled 
radiotracers, while a better contrast was obtained using [18F]DPA-714 
[62]. Evaluation of the PBR/TSPO radioligand with [18F]DPA-714 
and microPET was also performed in a rat model of focal cerebral 
ischemia. Significant increase in the specific binding of the 
radioligand could be measured in the ischemic hemisphere at 7, 11, 
15, and 21 days after ischemia reaching the maximum uptake at 11 
days. In vitro autoradiography confirmed these in vivo results. In vivo 
and in vitro [18F]DPA-714 binding was displaced from the lesion by 
PK11195 and DPA-714. Immunohistochemistry showed that 
increased TSPO expression was related to activated 
microglia/macrophage cells in the ischemic area [63].  
 
1.6. [18F]DPA-714  in mice  
 
The mouse has become a key model for studying human diseases 
because of the advantage to be easily maintained in a research services 
facility with respect to other animal species. Moreover, it could be 
considered an important surrogate model of genetic and not genetic 
disorders. Thus, the use of mouse models is of relevance to validate 
specific TSPO PET radiotracer and to study pathological changes in 
case of neuroinflammatory disease, in particular when combined with 
ex-vivo immunohistochemistry. In mice only few studies have been 
performed with [18F]DPA-714 and microPET and in  these studies the 
in vivo biodistribution and specificity of [18F]DPA-714 binding  in 
normal mouse have not been completely characterized and 
radiolabeled metabolites were not measured.  Ex-vivo biodistribution 
in mice showed, 60 minutes after the i.v. injection of [18F]DPA-714, 
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an high uptake in peripheral tissues known to be rich in TSPO with 
the highest accumulation in the heart, adrenal glands and kidney, 
whereas very low uptake was found in the brain [64]. Identification of 
radiometabolites of [18F]DPA-714 in the plasma and urines has been 
reported recently  in vivo and in vitro only in rats and in baboons. Ex-
vivo studies in rats revealed 15% of radiolabeled metabolite in the 
brain at 120 minutes after the radiotracer injection [65]. Moreover, the 
specificity and sensitivity of [18F]DPA-714 microPET in detecting NI 
changes in the SNC of NI models have to be further addressed. 
Significant increase in [18F]DPA-714 uptake could be measured in 
the ischemic brain area after transient middle cerebral artery occlusion 
[66-67]. The sensitivity and specificity of [18F]DPA-714 microPET 
in the study of NI in inflammatory and neurodegenerative models 
have not yet been reported.   
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1.7. Objective of the thesis 
 
The general aim of the present work was to validate the use of 
[18F]DPA-714 for the study of TSPO sites in vivo with microPET in 
mice models of NI.  
To this aim, we planned the following studies: 
1) Characterization of the in vivo biodistribution, specific binding and 
ex-vivo radiometabolites of [18F]DPA-714 in normal mouse  
2) Characterization of brain TSPO expression in a mouse model of 
Amyotrophic Lateral Sclerosis using [18F]DPA-714 and microPET 
and immunohistochemistry. 
3) Characterization of brain TSPO expression in a mouse model of 
Multiple Sclerosis using [18F]DPA-714 and microPET and 
immunohistochemistry. 
 
All the studies performed were approved by the animal welfare 
regulation committee (CESA) of the University “Federico II” of 
Naples and by the Italian Ministry of Health. It complied with the 
Guide for the Care and Use of Laboratory Animals published by the 
US National Institutes of Health (NIH Publication No. 85–23, revised 
1996). 
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2. Characterization of the in vivo 
biodistribution, specific binding and ex-vivo 
radiometabolites of [18F]DPA-714 in normal 
mouse 
 
The validation of [18F]DPA-714 is mandatory in order to assess 
whether it is a suitable radioligand for in vivo studies of TSPO sites in 
the brain and in the extracerebral regions of mice. [18F]DPA-714 has 
been characterized ex-vivo and in vivo with microPET in 
experimental models of neuroinflammation in rats. However, very few 
studies have investigated in detail the biodistribution and the specific 
binding to TSPO sites. In mice, to our knowledge, only one study [64] 
has previously reported, only in part and ex-vivo, the biodistribution 
of [18F]DPA-714 in healthy mice, while no in vivo microPET studies 
are currently available. Moreover, the measurement of radiolabeled 
metabolites has been done only in rat brain and liver [65]. The 
characterization of radiolabeled metabolites is a crucial step in the 
development of new radiotracers to better understand the behavior of 
the unchanged radiolabeled compounds for a more accurate 
quantification of TSPO. 
In this study we have characterized the biodistribution and the kinetics 
of [18F]DPA-714 in the brain and in the peripheral organs of healthy 
mice and we have evaluated the ability of large amount of unlabeled 
DPA-714 and PK1195 to inhibit [18F]DPA-714 binding using 
competitive studies. Moreover, we have quantified the presence of the 
main radiometabolites in different organs.  
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2.1. Materials and methods 
2.1.1. Mice  
Twelve to 18-weeks-old male C57BL/6J mice (body weight: 30.5 ± 
4.7) underwent PET/CT exam.  Mice were purchased from Charles 
River Laboratories (MI, Italy) and were housed in Plexiglas cages 
(36.5×20.7×14.0 cm), subjected to a 12 h light/dark cycle with ad 
libitum access to water and food (Mucedola® srl, Italy).  
2.1.2. PET studies: acquisition protocol and image analysis in 
healthy mice 
All the PET studies were performed under anesthesia induced  with 2 
L/min Oxygen plus Isoflurane 4% and maintained with 2% of  
Isofluorane delivered by a precision vaporizer (Vetequip 
incorporated®/Isoflurane vaporizer Funnel-Fill®) with a mice facial 
anesthesia mask connected to a coaxial non-rebreathing system 
(Vetequip incorporated®). Dynamic acquisitions (frames sequence: 
4×1 min, 3×2 min, 4×5 min, 4×10 min) were performed over 60–70 
minutes after intravenous (i.v.) injection of 5.55–7.00 MBq (30–87 
pmol), specific radioactivity (SRA) range: 80–300 GBq/μmol, mean ± 
SD = 120 ± 43 GBq/μmol) of [18F]DPA714 by tail vein, through the 
use of a catheter.  
Biodistribution studies were performed in 5 animals in which, 
[18F]DPA-714 was injected at trace doses. 
Pharmachological blocking studies were performed in 10 animals in 
order to assess the specific binding to TSPO sites. Intravenous 
injection of 1 mg/kg of unlabeled DPA-714 (n = 5) or 3 mg/kg of 
unlabeled PK11195 (n = 5) (PK11195 ABX advanced biochemical 
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compounds GmbH) was performed 5 minutes before [18F]DPA-714 
injection.  
For data analysis, time activity curves (TACs) were generated from 
circular regions of interest (ROI) manually drawn by over PET/CT 
fused images of brain, lungs, heart, liver, spleen and kidney, using 
PMOD software (v2.8; PMOD Technologies Ltd., Zurich, 
Switzerland). 
 
2.1.3. Ex-vivo studies: metabolite assay of [18F]DPA-714 in 
plasma and peripheral tissue of healthy mice 
 
Metabolite assay was carried out in five mice and PET images were 
also acquired in two of these mice. Sixty minutes after intravenous 
injection of [18F]DPA-714 mice were anesthetized and sacrificed by 
cervical dislocation. Brain, heart, lung, liver, kidneys, spleen, blood 
and urine were quickly removed and stored in ice. All peripheral 
organs were homogenized and centrifuged at 4° C and the supernatant 
was collected. The resulting soluble fraction was subjected to reversed 
phase (RP) high-pressure liquid chromatography (HPLC). The 
retention time (RT) of [18F]DPA-714 was 16.4 min. 
2.1.4. Statistical analysis 
Analysis of variance (ANOVA) was used to compared mean SUVs 
obtained at 30 and 60 minutes after the radiotracer injection between 
organs in the unsaturated group of mice (group 1) and in each organ 
between group 1, group 2 (saturated with unlabeled DPA-714) and  
group 3 (saturated with unlabeled PK11195). Least Significant 
Difference (LSD) post-hoc test was then used to localize differences 
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between organs and/or groups. The slopes of the SUVs over time were 
compared in group 1 between organs, and for each organ between the 
three groups by repeated measures ANOVA. 
 
2.2. Results 
2.2.1. [18F]DPA-714 PET/CT uptake 
Ten minutes after [18F]DPA-714 i.v. injection in C57BL/6J mice the 
highest concentration expressed as SUV, was observed in the lungs, 
followed by heart, kidneys, spleen and liver, while the brain presented 
the lowest SUV values. Radiotracer clearance was faster in the lung 
than in the brain and heart, whereas spleen concentration remained 
almost constant for the entire duration of the exam. In contrast, tracer 
concentration increased in kidneys and in liver. At 30 min after 
[18F]DPA-714 injection, activity was reduced  to 64% of the 10 min 
value in the lung, 71% in the brain and 90% in the heart while in the 
kidneys and in liver increased to 34% of the 10 min values (Fig. 7 A). 
Repeated measures ANOVA showed that the slopes of the SUVs over 
time significantly decreased in lung, brain and heart (p<0.0001) 
whereas they significantly increased in spleen (p<0.05), kidneys 
(p<0.0001) and liver (p<0.005). The organ/brain ratios were 
significantly lower (p<0.001 at ANOVA followed by LSD post-hoc 
tests) in liver, compared to those of lung, heart and kidneys at 30 min, 
and significantly higher in kidneys compared to all other organs at 60 
min post-injection. 
 
29 
 
 
Fig 6. Representative coronal PET images at the level of lungs and kidneys (first and third 
columns) and heart (second and fourth columns), at 30 and 60 minutes (on the left and on the right 
respectively) post-injection of [18F]DPA-714. Scans were performed at trace dose (A), after pre-
injection of 1mg/kg of DPA-714 (B) and of 3mg/kg of PK11195 (C). R and L indicate right and 
left side of animals (Vicidomini et al. 2015) [68].  
 
2.2.2. Blocking studies with DPA714 and PK11195 
Pre-injection of large doses of unlabeled DPA-714 (Fig. 7B) and 
PK11195 (Fig. 7C), dramatically reduced heart and lung radiactivities 
at 30 and 60 min post-injection.  In contrast, kidneys uptake was 
reduced at 60 minutes post-injection with DPA-714, but not with 
PK11195, while liver activity was increased, although not 
significantly. Statistical analysis confirmed these visual findings. The 
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wash-out of the radiotracer in lung and heart was significantly slower 
in the blocking studies (p<0.001) compared with unblocked studies 
(group 1), while the increase of radioactivity over time in spleen was 
significantly (p<0.05) reduced in the blocking studies.  
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Fig 7. Time activity curves (mean ± SD) of SUV values after [18F]DPA-714 injection at trace 
dose (A), and after pre-saturation of TSPO binding sites with DPA-714 (B) or PK11195 (C), 
injected 5 minutes before the radioligand (Vicidomini et al. 2015) [68]. 
 
Resulting mean SUV values at 30 and 60 min showed significant 
difference at ANOVA between unsaturated and blocking studies in all 
regions (p range: 0.05–0.0001). Post-hoc analysis revealed that at 30 
min after the radiotracer injection in comparison to group 1, SUV 
values were significantly reduced in group 2 and 3 in lung (−79%, 
p<0.0001; −72%, p<0.0001 respectively), heart (−80%, p<0.0001, 
72%, p<0.0001 respectively) and spleen (−52%, p<0.05, −47%, 
p<0.05). In contrast, in kidneys SUV values were significantly 
reduced in group 2 (-29%, p<0.05) and non-significantly increased in 
group 3 (+9%, p=0.5). This resulted in a significant difference 
between group 2 and 3 (p<0.01). In liver, there was an increase of 
SUV value in group 2 and 3 as compared to group 1, significant only 
in group 3 (+40 %, p=0.09,+146%, p<0.001. respectively). In group 3 
the SUV values were also significantly higher than in group 2 
(p<0.001). SUV values of brain were also reduced in group 2 and 3 in 
comparison to group 1 but only the reduction of 3 group is significant 
(−18%, p=0.232; −53%, p<0.01 respectively).  
2.2.3. Metabolite assay 
No measurable radiometabolites were identified at 60 min in brain, 
lung, spleen and heart. In kidneys, a radiometabolite was observed at 
RT 14.7 minutes. In liver, two radiometabolites were identified at RT 
13.4 and 15.1 minutes, representing averaged values of 3.8% and 
11.5% of the total radioactivity, respectively.  
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2.3. Summary and discussion 
 
In this study we have characterized the in vivo biodistribution and 
specific binding of [18F]DPA-714 in the brain and in peripheral 
tissues of normal mice using microPET/CT. We showed that 
[18F]DPA-714 uptake was high in the lung, heart and kidney, 
intermediate in the spleen and very low in the brain. The regional 
time-activity curves revealed that the wash-out of [18F]DPA-714 is 
different among regions: faster in the lung, heart and brain and slower 
in the spleen and kidney. More importantly, blocking studies revealed 
that [18F]DPA-714 could significantly and highly inhibited in all 
these regions. Overall these results demonstrated that the binding of 
[18F]DPA-714 is specific for TSPO sites. The regional biodistribution 
of [18F]DPA-714 observed in healthy mice is consistent with previous 
in vitro and ex-vivo findings on TSPO localization in the brain and in 
the peripheral tissues of rodents, using other radiotracers [49-69-70]. 
The uptake of [18F]DPA-714 is also consistent with the distribution of 
[18F]DPA-714 in ex-vivo studies of mice [64] and in vivo studies of 
rats [49]. The kinetic studies of [18F]DPA-714 showed that 
radiotracer uptake in heart at late times was lower than that in lungs, a 
finding in apparent discrepancy with previous data in primates [59-
65] and in healthy volunteers [64]. This discrepancy might be in part 
explained by partial volume effects due to the low spatial resolution of 
micro-PET camera used, with respect to small size of cardiac wall, a 
region rich in TSPO receptor resulting in underestimation of heart 
SUV. 
Blocking studies confirmed the specificity of [18F]DPA-714 binding 
for TSPO in mice, in particular pre-injection of unlabeled DPA-714 or 
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PK11195 reduced radiotracer uptake by 80% and 72% respectively in 
lung and heart at 30 minutes after injection, by 2% and 47% in spleen 
and by 17% and 46% in brain. The behavior of DPA714 and PK11195 
was different in blocking studies in the kidney where pre-injection of 
DPA-714 but not of PK11195 significantly reduced [18F]DPA-714 
uptake of by 29% and 46% at 30 and 60 minutes, respectively. 
Another important result was that at 30 and 60 minutes unlabeled 
PK11195, but not DPA-714, reduced [18F]DPA-714 uptake in the 
brain [68]. These discrepancies could be in part attributed to binding 
at different sites on the TSPO macromolecule, different metabolism 
rates and/or different blood kinetics. 
In this study we also showed that radioactivity in brain, lung, heart 
and spleen was essentially due to the intact form of [18F]DPA-714 
and not to radiolabeled metabolites. The lack of measurable amount of 
radiometabolites in brain at 60 min is in part attributable to the 
presence of only 15% of radiometabolites in the brain of rats at 120 
min after [18F]DPA-714 injection [65]. However, it should be 
considered that minimal discrepancies might be due to different 
methods used. Our method was a little less sensitive than that used in 
the previous rat study [65]. In the kidneys there was a small amount of 
one radiometabolite at RT 14.7 minutes, while in the liver we found 
two radiometabolites at RT 13.4 and RT 15.1 minutes (3.8% and 
11.5% of the total radioactivity, respectively). To date, 
radiometabolites of [18F]DPA-714 have been tested in blood samples 
of rats and baboons, in rat brain homogenates [61-65]  and in rat and 
human liver microsomes [65].Thus our results provide additional new 
informations useful for future use and quantification of  [18F]DPA-
714 in healthy mice and in animal mice models.  
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The results of this study have been the object of a publication:   
Vicidomini C, Panico M, Greco A, Gargiulo S, Coda AR, Zannetti A, 
et al. In vivo imaging and characterization of [18F]DPA-714, a 
potential new TSPO ligand, in mouse brain and peripheral tissues 
using small-animal PET. Nucl Med Biol 2015; 42: 309-16 [68].  
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3. Characterization of brain TSPO expression 
in a mouse model of Amyotrophic Lateral 
Sclerosis using [18F]DPA-714 and microPET 
and immunohistochemistry.  
 
PET imaging and TSPO radiotracers such as [11C]PK11195 and 
[18F]DPA-714 have been first used in patients with sporadic ALS and 
provided evidence of increased binding in different cerebral regions 
including motor cortex, prefrontal cortex and thalamus [2]. In a 
pioneering study in ALS patients, using PET and [11C]PK11195,  
revealed a significant increased binding in the motor cortex, pons, 
dorsolateral prefrontal cortex and thalamus [71]. More recently, using 
a second-generation TSPO radioligand such as [18F]DPA-714 and 
[11C]PBR28, increased binding was confirmed in similar brain  
regions, compared to healthy controls [72-73]. Post-mortem studies 
using [3H]PK11195 and [3H]DAA1106 in tissues from patients with 
ALS, showed that in the motor cortex specific binding of both ligands 
correlated with the presence of activated microglia identified by 
immunohistochemistry with CD68 antibody [74].  To our knowledge, 
no in vivo studies have demonstrated that increased TSPO expression 
in the brain and in the spinal cord of ALS might be related to 
microglial activation. The use of animal models is of relevance for 
validation of PET TSPO radiotracers, in particular when combined 
with immunohistochemistry, because allows characterization of 
histopathological and cellular changes underlying in vivo PET images. 
Moreover, it could be a useful tool for monitoring NI changes from 
the presymptomatic stage and the evaluation of the effects of therapy.  
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In this study, we have characterized both in vivo with PET/CT and 
[18F]DPA-714, and ex-vivo with immunohistological analysis the 
TSPO expression and microglial activation in the SNC of transgenic 
SOD1 G93A mice, the most used and well characterized model of 
ALS.  
3.1. Materials and methods 
3.1.1. SOD1 G93A transgenic mouse model 
Experiments were carried out in adult male transgenic hemizygous 
B6SJL-Tg[SOD1*G93A]1Gur/J mice (SOD1 G93A; stock number 
002726), expressing a high copy number (about 29) of the mutant 
human SOD1 allele with a Gly93Ala substitution, that are 
characterized by survival times of 128.9±9.1 days. Transgenic 
hemizygous B6SJL-Tg(SOD1)2Gur/J (WT SOD1; stock number 
002297), carrying the normal allele of the human SOD1 gene, served 
as controls for the SOD1 G93A strain, as it has been reported that WT 
SOD1 mice express the same level of SOD1 protein as SOD1 G93A 
mice and do not develop MN degeneration [24]). Mice were 
purchased from Jackson Laboratories (Bar Harbor, ME) via Charles 
River (Calco, LC, Italy) and were housed in group cages under a 
12h/12h light/dark cycle and were allowed free access to food and 
water. 
 Disease progression and clinical score: to determine disease onset and 
progression, mice were monitored three times a week starting at 50 
days of age using the clinical score system (CS) described by 
Solomon et al [75]. A numerical scale from 0 to 5 was used to identify 
the severity of disease: 0 no evidence of disease, 1 shaking or splaying 
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of the hind limbs when suspended by the tail, 1.5 weakness in one 
hind limb, 2 change in gait (toes curl under at least twice during 
walking, or any part of foot is dragging along cage bottom/table), 2.5 
extreme weakness in one hind limb, 3 extreme weakness in both hind 
limbs, 3.5 functional paralysis in one hind limb, 4 functional paralysis 
in both hind limbs but can right themselves in less than 20 seconds 
after being placed on their side, 5 cannot right themselves to sternum 
within 20 seconds after being placed on their side (endpoint) [75]. 
SOD1 G93A mice with advanced symptoms of ALS had a source of 
hydration and energy placed on the cage floor, and electrolyte 
balanced solutions were provided parenterally. Body weight and body 
condition score were evaluated three times a week, as described 
elsewhere [75]. Mice were euthanized after reaching a score of 4 
according to the guidelines for preclinical testing and colony 
management [76]. 
 
3.1.2. PET studies: acquisition protocol and image analysis for 
G93A SOD1 mouse model 
 
Nine symptomatic SOD1 G93A mice aged from 117 ± 12.75 days 
(mean age ± SD) with CS ranging from 1 to 4 and five congenic 
controls WT SOD1 aged from 108 ± 28.5 days were anesthetized as 
reported in paragraph 2.1.2 and underwent PET/CT. Images were 
acquired in dynamic mode (frame sequence: 6×5 min) over 30 min 
starting 20 min after injection via a tail vein of 5.55–7.00 MBq 
(specific radioactivity 200–800 GBq/μmol) of [18F]DPA-714. Count 
rates were converted to SUV and PET frames acquired between 20 
and 50 min were summed and used for data analysis. Regions of 
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interest (ROIs) were manually defined on summed axial PET images 
based on PET/CT fusion images using the mouse brain atlas of 
Paxinos and Franklin for guidance [77]. ROIs were placed on 
cerebellum, brainstem, upper part of the cervical spinal cord, motor 
frontal cortex and frontal association cortex, over at least three 
consecutive slices using OsiriX 5.8.5 imaging software (Pixmeo, 
Bermex, Switzerland). For each brain region, [18F]DPA-714 SUVs 
were calculated by pooling the ROIs defined over consecutive slices. 
SUV ratios were calculated by normalizing the cervical spinal cord 
(rCSC), cerebellar (rCRB), brainstem (rBS), and motor cortex 
(rMCX) activities to that of the frontal association cortex. This 
normalization was performed to reduce between-animal variability in 
radiotracer uptake. The frontal association cortex was used for 
normalization because this region is unaffected in SOD1 G93A mice.  
 
 
3.1.3. Ex-vivo studies: SOD1 G93A mice tissue processing for 
immunohistochemical studies and confocal acquisition 
 
Prefrontal cortex, motor cortex, cerebellum, brainstem motor nuclei 
and cervical, thoracic and lumbar tracts of spinal cord were analyzed.  
Two control WT SOD1 and six symptomatic SOD1 G93A mice, one 
CS of 2, one CS of 2.5 and four CS of 4 (median CS 4), were studied. 
All animals underwent PET from 1 to 9 days before euthanasia (mean 
± SD 5 ± 3 days) except one SOD1 G93A mouse with a CS of 2. In 
one of the symptomatic SOD1 G93A mice with a CS of 4 only the 
motor cortex and spinal cord were available for immunofluorescence. 
For the exact anatomical identification we used the mouse brain atlas 
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of Paxinos and Franklin [77]. Images were observed using a confocal 
microscope Zeiss LSM 700. 
 
3.1.4. Statistical analysis 
 
Descriptive statistics for body weight, BCS and CS was performed in 
both SOD1 G93A and WT SOD1 mice. The clinical and [18F]DPA-
714 SUV data were analyzed using the software package SPSS 
version 11 (SPSS, Chicago, IL). The nonparametric Mann-Whitney 
test was used to compare [18F]DPA-714 SUVs of the frontal 
association cortex, and rCSC, rCRB, rBS and rMCX between SOD1 
G93A and WT SOD1 mice. The nonparametric Spearman’s rank 
correlation coefficient was used to determine the correlation between 
age and CS and regional SUV ratios in SOD1 G93A mice. The level 
of significance was set at p≤0.05. 
 
3.2. Results 
3.2.1. Clinical score and body weight 
SOD1 G93A mice became symptomatic from 95 days of age (mean ± 
SD: 102.8 ± 7.04 days, range 95–110 days) and progressively 
worsened (CS score from 1 to 4, and BCS score from 3 to 2). WT 
SOD1 controls remained healthy (CS 0, BCS 3). The average body 
weight in SOD1 G93A mice was significantly lower than that of WT 
SOD1 mice from the age of 14 weeks (mean ± SD: 26.55 ± 2.49 g vs. 
31.29 ± 1.84 g, respectively; p = 0.027), with the difference in body 
weight increasing with disease progression (Fig 8).  
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Fig. 8 Body weight (mean±SD) registered from 7 to 19 weeks of age in SOD1 G93A and WT 
SOD1 mice (Gargiulo et al. 2016 Electronic supplementary material) [87]. 
 
3.2.2. [18F]DPA-714 PET/CT uptake 
PET images showed a clear increase of [18F]DPA-714 uptake in 
brainstem and in cervical tract of spinal cord of symptomatic SOD1 
G93A mice as compared to WT SOD1 mice while the uptake in the 
anterior cerebral regions appeared lower (Fig. 9).  
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Fig. 9 Representative PET/CT fusion images at the level of brainstem in a WT SOD1 control 
mouse (a) and in a symptomatic SOD1 G93A mouse, obtained from summation of scans between 
20-50 min after [18F]DPA-714 injection. SUV values were normalized to those of the frontal 
association cortex and scaled at a maximum value of 8. A higher radiotracer uptake is evident in 
the brainstem of symptomatic mouse (white arrows) as compared to control mouse. Red arrow 
shows an increased uptake also in cervical spinal cord in sagittal view of symptomatic SOD1 
G93A mouse.  
 
Since differences between average SUV of frontal association cortex 
in SOD1 G93A and WT SOD mice, were not significantly (0.207 ± 
0.090 and 0.225 ± 0.105, respectively; p = 0.787), we used this region 
as reference to generate regional SUV ratios.  In symptomatic mice, 
the regional SUV ratios were significantly increased compared with 
WT SOD1 controls only in rBS (2.340 ± 0.784 and 1.576 ± 0.287 
respectively,   p = 0.014). The rCSC mean values were increased by 59 
% in symptomatic SOD1 G93A mice as compared to WT SOD1 
controls, but the averaged values (3.243 ± 1.408 and 2.084 ± 0.551 
respectively) were not significant (p = 0.053). Similarly, no significant 
differences between symptomatic SOD1 G93A mice and WT SOD1 
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controls were found in rCRB (2.063 ± 0.612 and 1.691 ± 0.364 
respectively, p=0.162) and rMCX values (1.090 ± 0.242 and 0.928 ± 
0.101 respectively, p=0.162). In symptomatic SOD1 G93A mice, CS 
showed a statistically significant correlation with age (R = 0.786, p ≤ 
0.05), whereas there was no significant correlation between CS and 
[18F]DPA-714 SUV ratios (Fig. 10).  
 
 
Fig 10 [18F]DPA-714 SUV values reported in histogram for cervical spinal cord (rCSC), 
cerebellum (rCRB), brainstem (rBS) and motor cortex (rMCX) in WT control mice compared to 
symptomatic G93A SOD 1 mice (*p<0.02). 
 
3.2.3. Immunohistochemistry  
 
Increased expression of TSPO in Iba1 positive cells was found in the 
brainstem of symptomatic SOD1 G93A mice, while in WT SOD1 
controls, Iba1 and TSPO immunolabeling were weak. In particular, in 
SOD1G93A mice with CS of 4 a strong increase of Iba1 positive cells 
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was observed in the trigeminal, facial, ambiguus, hypoglossal nuclei. 
Iba1 positive cells showed a clear morphological change characterized 
by enlargement of body cell and shortening of cellular processes. 
Moreover, activated microglial cells revealed a perfect colocalization 
with TSPO immunoreactivity (Fig. 11). Iba1 and TSPO expression 
was also higher in SOD1 G93A mice with a CS of 2 – 2.5 than in WT 
SOD1 controls, although the difference was not as great as in SOD1 
G93A mice with a CS of 4.  
 
Fig 11 Confocal laser scanning microscopy images of TSPO and Iba1 immunofluorescence in 
ambiguus nucleus (A) and facial nucleus (B) of a symptomatic SOD1 G93A at CS 4 and a WT 
control mouse. TSPO immunolabeling (in red), Iba1 immunolabeling (in green) and merged 
images (in orange). 
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Elevated expression was also found in motor cortex (Fig. 12 A) and in 
cerebellum (Fig. 12 B). However, Iba1 and TSPO expression in the 
frontal association cortex was not present in SOD1 G93A mice and in 
WT SOD1 controls (data not shown).  
Increased Iba1 and TSPO expression could be also clearly observed in 
the cervical (Fig. 12 C), thoracic and lumbar tracts of spinal cord in 
SOD1 G93A mice compared to controls, more marked in animals with 
CS of 4.   
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Fig. 12 Confocal laser scanning microscopy images of TSPO and Iba1 immunofluorescence in 
motor cortex (A), cerebellum (B) and cervical spinal cord (C) of a symptomatic SOD1 G93A at 
CS 4 and a WT control mouse. TSPO immunolabeling (in red), Iba1 immunolabeling (in green) 
and merged images (in orange). 
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3.3. Summary and discussion 
The results of this study are the first to be reported in SOD1 G93A 
mice, a model of ALS, using microPET, a radioligand for TSPO sites 
and immunohistochemistry. They suggest that a significant increase in 
[18F]DPA-714 uptake can be measured in vivo with high-resolution 
PET/CT in the brainstem of symptomatic SOD1 G93A mice. 
Moreover, immunostaining showed that increased TSPO expression in 
the brainstem nuclei was colocalized with Iba1 immunoreactivity, 
underlying the important contribution of microglial activation to the 
increased brainstem [18F]DPA-714 uptake. In contrast, transgenic 
mice over-expressing the nonmutated wild-type human SOD1 did not 
show increased [18F]DPA-714 uptake in vivo as well as increased 
TSPO and Iba1 expression ex-vivo. The low spatial resolution of PET 
scanner did not allow identifying individual brainstem nuclei, instead 
the combined results with immunofluorescence studies demonstrated 
that increased TSPO and Iba1 expression in specific motor nuclei, 
such as the trigeminal, facial, ambiguus and hypoglossal, might 
underlie increased [18F]DPA-714 brainstem binding measured in vivo 
in symptomatic SOD1 G93A mice.  
Our findings are in line with previous post-mortem studies showing 
that these brainstem nuclei are site of strong inflammatory reaction in 
SOD1-ALS transgenic mice. Interestingly, in the same brainstem 
nuclei post-mortem studies [78-79], and in more recent in vivo MRI 
studies [80], degenerative changes were markedly showed, suggesting 
a link between NI and neurodegeneration of motor nuclei in this ALS 
model. Inflammatory changes seem to appear earlier than 
neurodegenerative changes, suggesting that NI even in 
neurodegenerative disorders might be an interesting therapeutic target.   
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Previous studies indicated that SOD1-ALS transgenic mice also show 
more widespread inflammatory changes involving other brain regions 
than the spinal cord and brainstem including the cerebellum [80-81] 
and the motor cortex [82-83]. Nevertheless, in this work [18F]DPA-
714 binding in the cerebellum and motor cortex showed no significant 
increase. Only in two symptomatic SOD1 G93A mice, with severe 
clinical score, ex-vivo immunohistochemistry showed increased Iba1 
and TSPO immunoreactivity in motor cortex in one and in the 
cerebellum in the other one. Further studies are recommended. We 
failed to measure with PET significant in vivo changes in [18F]DPA-
714 uptake in the spinal cord. This is in contrast with our results of 
immunostaining performed in the same animals and showing 
increased TSPO expression in the entire spinal cord, accompanied by 
a good colocalization with Iba1 immunoreactivity in agreement with 
previous postmortem findings of increased microglial expression in 
spinal cord of transgenic SOD1 G93A mice [84-85], and more recent 
in vivo PET data showing increased [11C]PBR28 binding in the spinal 
cord of symptomatic SOD1 G93A mice [86]. 
This suggests that PET with [18F]DPA-714 is not sensitive enough to 
detect microglial activation and increased TSPO expression in mice, at 
least at the cervical level using our microPET camera.  
The results of this study have been the object of a publication: 
Gargiulo S, Anzilotti S, Coda AR, Gramanzini M, Greco A, Panico 
M, et al. Imaging of brain TSPO expression in a mouse model of 
amyotrophic lateral sclerosis with 18F-DPA-714 and micro-PET/CT. 
Eur J Nucl Med Mol Imaging 2016, 43: 1348-1359 [87]. 
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4. Characterization of brain TSPO expression 
in a mouse model of Multiple Sclerosis using 
[18F]DPA-714 and microPET and 
immunohistochemistry. 
 
In MS animal models, PET studies have been undertaken to monitor 
NI changes using glucose metabolism and more recently specific 
TSPO PET radioligands [88].  Increased [18F]FDG PET uptake was 
reported in spinal cord of C57BL/6 mice from day 8 to 21 after 
immunization [89] and of dark agouti rats between 10-14 days from 
immunization [90] with MOG peptide, an EAE chronic-progressive 
model. The increased [18F]FDG uptake was associated with the 
presence of inflammatory infiltrates as determined by histology [89-
90] and correlated especially with CD68-positive cells in rats [90]. 
Moreover, immunosuppressive therapy with dexamethasone, 
performed in mice, reduced glucose metabolism in the spinal cord 
[89]. Although the changes in glucose metabolism detected with 
[18F]FDG and anatomical location of the PET signal are suggestive of 
the presence of inflammatory infiltrates, this radiotracer is not a 
specific marker of NI. Other important limits are the high background 
activity in the CNS due to the high physiologic glucose consumption 
of the brain and the lack of specificity for glial cells.  
Recently, PET studies in different EAE rats and mice models have 
focused on the evaluation of more specific molecular biomarkers of 
cells involved in NI, in particular microglia and astrocytes, such as 
TSPO.  Among these, [18F]DPA-714 has been also applied to explore 
the expression of TSPO in a rat model of acute monophasic EAE-
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MBP. The distribution of radioactivity showed an increased uptake in 
thoracic and lumbar spinal cord, fivefold higher than control animals. 
The specificity of [18F]DPA-714 binding was confirmed in 
competition studies, using unlabeled PK11195 or DPA714. Moreover, 
immunohistochemical staining showed that TSPO expression 
colocalized with activated microglia and macrophages, but not with 
astrocytes. In this study the binding of [18F]DPA-714 was not 
investigated in the brain because inflammatory changes in this model 
are prevalent in the spinal cord [91]. 
The sensitivity of [18F]DPA-714 and microPET has not been assessed 
in mice MS models and in particular in EAE model associate to both 
spinal cord and brain NI changes.  
In this study, we have characterized both in vivo with PET/CT and 
[18F]DPA-714, and ex-vivo with immunohistological analysis the 
TSPO expression and microglial activation in the SNC of an EAE 
model induced in SJL/J by mice immunized with PLP. This model 
mimics the relapsing remitting clinical form of human MS and 
involves both the spinal cord and brain regions [92].  
 
 
4.1. Materials and methods 
4.1.1. EAE mouse model and induction of disease 
Female SJL/J mice at 6 weeks of age were purchased from Charles 
River (Calco, LC, Italy) and were housed in group cages under 
standard conditions with free access to food and water. Mice were 
51 
 
allowed to acclimatize for one week before the start of any 
experiment.  
On day 0, EAE symptomatic animals were subcutaneously immunized 
at each of two sites at the base of the tail with an emulsion of equal 
volumes of the proteolipid protein PLP139-151 (Inbios) in complete 
Freund’s adjuvant (CFA, Becton Dickinson Italia) supplemented with 
4mg/ml inactivated Mycobacterium tuberculosis H37RA (Becton 
Dickinson Italia). The initial immunization was followed by 
intraperitoneal administration of 2ng/ml Bordetella pertussis toxin 
(BPX, Sigma Aldrich) in PBS (phosphate buffered saline) on the same 
day (day 0) and the following day (day 1). During all procedures of 
immunization, mice were gently handled, to avoid stress and 
anesthesia was not used. In some mice, obvious bumps developed at 
the injection sites 2 to 4 days after immunization. Rarely alopecia 
developed at the site of injection. Control animals received same 
procedures of immunization, but PLP139-151 were replaced with PBS 
[93]. 
Neurological assessment and clinical score: animals were monitored at 
least daily, every day including weekends. Clinical signs began with 
motor deficits characterized by an ascending paralysis starting from 
the tail. Animals with initial symptoms were isolated in separate cages 
with easier access to food and water, and all dehydrated animals 
received an intraperitoneal injection of saline solution at least once a 
day. Clinical signs were graded on a five-point scale: 0 no obvious 
changes in motor function, 0.5 tip of tail is limp, 1 limp tail, 1.5 hind 
leg inhibition, 2 weakness of hind legs, 2.5 dragging of hind legs, 3 
paralysis of hind legs, 3.5 hind legs are completely paralyzed and 
together on one side of body, 4 complete hind leg and partial front leg 
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paralysis, 4.5 no movements around the cage, euthanasia is 
recommended, 5 death due to paralysis [94].  
 
4.1.2. PET studies: acquisition protocol and image analysis for 
EAE mouse model 
Seventeen EAE symptomatic mice from 11 to 25 days post 
immunization, with CS ranging from 0 to 4 and seven control mice 
were anesthetized with isoflurane and injected via tail vein, with 5 – 
10 MBq (specific radioactivity 200–800 GBq/μmol) of [18F]DPA714. 
PET acquisition started 20 minutes after radiotracer injection and 
lasted 30 minutes. Images were acquired in dynamic mode (frame 
sequence: 6×5 min) ROIs were manually defined on summed images 
based on PET/CT fusion images using the mouse brain atlas of 
Paxinos and Franklin for guidance [77]. Circular ROIs were placed on 
the olfactory bulbs (OB), prefrontal cortex (PFC), cerebellum (CBR), 
brainstem (BS) and the upper part of cervical spinal cord (CSC) using 
PMOD imaging software. Also for this model, as for G93A SOD1 
transgenic mice, thoracic and lumbar spinal cord were excluded from 
analysis because their small size can be influenced by partial volume 
effects. SUV ratio values were obtained using frontal cortex value to 
normalize values of all other regions (rOB, rCBR, rBS, rCSC). Frontal 
cortex is unaffected region in EAE PLP139-151 and it did not show 
significant differences between symptomatic and control mice. Thus, 
it was used as reference for normalization.  
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4.1.3. Ex-vivo studies: EAE mice tissue processing for 
immunohistochemical studies and confocal acquisition 
 
After in vivo studies, EAE symptomatic and control mice were 
anaesthetized with isoflurane 4%, transcardially perfused and 
underwent to the same procedures for ex-vivo studied used for SOD1 
G93A mouse model.  
Five control EAE mice and seven symptomatic EAE mice, one CS of 
0.5, one 1.5, one CS of 2.5, three CS of 3.5 and one CS of 4 (median 
CS 3.5), were analyzed. All animals underwent PET studies before 
euthanasia for ex-vivo studies. Frontal motor cortex, corpus callosum, 
striatum, cerebellum, brainstem and cervical, thoracic and lumbar 
tracts of spinal cord were analyzed. The mouse brain atlas of Paxinos 
and Franklin was used for a correct identification of all regions [77].  
 
4.1.4. Statistical analysis 
Non parametric Mann-Whitney test was used to compare [18F]DPA-
714 SUV values of region/prefrontal cortex ratios between EAE 
symptomatic and control mice. In addition, Pearson's correlation 
coefficient was used to determine the correlation between clinical 
score and regional SUV ratios in all EAE mice (clinical score range: 
0-4). The level of significance was set at p≤0.05. 
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4.2. Results 
4.2.1. Clinical score and body weight 
EAE mice became symptomatic between the tenth and the eleventh 
days after PLP139-151 immunization, followed by a peak between the 
twelfth and fifteenth days and a subsequent recovery that was almost 
complete from 16 until 25 days, the last day of our study  (Fig. 13).  
 
 
Fig 13 Clinical score (mean±SD) registered from 0 to 25 day after immunization in EAE mice. 
 
 
Weight of EAE animals started to decrease just before the appearance 
of the first clinical symptoms and then recovered when the mice 
became asymptomatic (Fig. 14).  
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Fig. 14 Body weight (mean±SD) registered from 0 to 25 day after immunization in EAE and 
control mice. 
In the whole group, the clinical symptoms appeared at 11 ± 1,22 days, 
and peaked at 12,82 ± 1,42 days. At peak the averaged clinical score 
was of 2,56 ± 0,86 CS. The averaged weight bodies at the beginning 
of symptoms was 18,84 ± 2,30 g and reached the values of 16,64 ± 
1,79 g  at peak.   
 
4.2.2. [18F]DPA-714 PET/CT uptake 
 
The average SUV of prefrontal cortex in EAE mice was not 
significantly increased if compared to controls (0.227 ± 0.112 and 
0.304 ± 0.139 respectively; p = 0.349). The radiotracer uptake in 
olfactory bulbs, cerebellum and brainstem showed a clear increase in 
symptomatic mice, while anterior regions of brain did not present any 
change (Fig. 15).  
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Fig. 15 Sagittal PET images (20-50 min) co-registered to CT in EAE mice and in a control. 
Increased [18F]DPA-714 uptake is present in the brainstem and cerebellum. Higher uptake seems 
to be more marked with the increase of clinical score (CS) (Coda et al. 2014) [95]. 
 
 
In 15 symptomatic EAE mice (clinical score range: 0.5-4), [18F]DPA-
714 SUV ratios were significantly increased compared to controls in 
the orbitofrontal cortex (rOB: 1.408 ± 0.205 vs 1.172 ± 0.217; p = 
0.022), in the cerebellum (rCBR: 1.755 ± 0.319 vs 1.321 ± 0.167; p = 
0.002) and in the brainstem (rBS: 1.738 ± 0.343 and 1.359 ± 0.283; p 
= 0.014). Although visual assessment of PET images proved an 
increased [18F]DPA-714 uptake also in the upper tract of cervical 
spinal cord, this difference was not significant between EAE mice 
(2.220 ± 0.611) and control mice (1.874 ± 0.707) (p = 0.183) (Fig. 
16).  
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Fig 16 On the right there are the results of PET semiquantification of [18F]DPA-714 uptake using 
normalization to the frontal cortex. These results show significant increase of [18F]-DPA-714 
uptake in the brainstem, cerebellum and olfactory bulb in symptomatic EAE with respect to 
controls. 
 
A significant positive correlation (p<0.059 was found between the 
increase of [18F]DPA-714 SUV ratios values in the cerebellum and in 
the brainstem and the increase of clinical score of severity.  
In particular, for cerebellum the best fit linear correlation is 
y=0.1407x+1.5359 with a coefficient R² = 0.2545 (Fig. 17a) and for 
brainstem linear equation is y=0.1659x+1.4798 with a coefficient R² = 
0.3064 (Fig. 17b).  
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Fig. 17 Linear correlation between [18F]DPA-714 and CS in cerebellum (a) and brainstem (b). 
 
 
4.2.3. Immunohistochemistry  
 
TSPO expression and microglial activation were evaluated in different 
areas of brain and spinal cord of symptomatic EAE and control mice 
underwent PET and immunofluorescence and preliminary data 
suggest that increased expression of TSPO in the posterior part of 
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brain with cerebellum and brainstem and spinal cord was significantly 
expressed in Iba1 positive cells. Preliminary results of double 
immunohistochemical analysis revealed an immunoreactivity much 
higher in symptomatic EAE mice, than control mice. In cerebellum, 
Iba1 positive cells were strongly increased in EAE mice with high CS, 
showing a morphological change characterized by enlargement of the 
cell body and shortening of cellular processes. TSPO 
immunoreactivity was localized mainly in Iba1 cells (Fig. 18 A). In 
brainstem, an abundant TSPO immunoreactivity was distribuited in 
Iba1 cells characterized by a larger shape, with a good colocalization 
with TSPO (Fig. 18 B). 
 
Fig. 18 Confocal laser scanning microscopy images of TSPO and Iba1 immunofluorescence in 
cerebellum (A) and brainstem (B) of a symptomatic EAE mouse at CS 2.5 and a control mouse. 
TSPO immunolabeling (in red), Iba1 immunolabeling (in green) and merged images (in orange). 
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In cervical, thoracic and lumbar tract of spinal cord, Iba1 dual-label 
study showed an important immunolabeling increase in EAE 
symptomatic mice. In cervical tract Iba1 positive cells displayed a 
significant increase associated with an abundant TSPO 
immunoreactivity (Fig. 19 A). Thoracic spinal cord showed a strong 
increase of Iba1 immunoreactivity accompanied by a morphological 
change and a complete colocalization with an intense TSPO activation 
(Fig. 19 B). Also in lumbar tract dual-label study, TSPO 
immunoreactivity appeared significantly abundant and distributed 
principally in Iba1 cells with larger shape and shorter cellular process 
(Fig 19 C).  
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Fig. 19 Confocal laser scanning microscopy images of TSPO and Iba1 immunofluorescence in 
cervical (A), thoracic (B) and lumbar (C) tract of spinal cord of a symptomatic EAE mouse at CS 
2.5 and a control mouse. TSPO immunolabeling (in red), Iba1 immunolabeling (in green) and 
merged images (in orange). 
 
High TSPO and Iba1 expression was found in the motor cortex and 
corpus callosum of two different EAE mice at CS of 3.5 and 2.5. 
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Striatum, hippocampus and thalamus were also observed but TSPO 
and microglial activation did not present. Finally, in EAE mouse at CS 
of 1.5, TSPO immunolabeling was very low in the different regions 
and some Iba1 positive cells displayed a small cell body and ramified 
morphology. TSPO immunoreactivity partially colocalized with 
microglia. In control mice, TSPO and Iba1 immunolabeling were very 
weakly expressed or almost completely absent in all regions 
examined.  
 
4.3. Summary and discussion 
 
The preliminary results of our study suggest that increased [18F]DPA-
714 uptake can be measured with microPET in the olfactory bulb, in 
the cerebellum and in the brainstem of symptomatic mice with RR-
EAE compared to controls mice. The increase of [18F]DPA-714 
binding in the cerebellum and in the brainstem is related to the degree 
of clinical severity. In addition, the results of immunofluorescence 
studies revealed that in these regions there was an increase of TSPO 
immunolabeling that colocalized with Iba1 positive cells. Overall 
these results demonstrated that increased microglial activation 
characterizes the brain of EAE-PLP mice and can be detected in vivo 
with the TSPO radioligand [18F]DPA-714. These findings are in 
agreement with those reported in vivo with microPET using a 
different radioligand, the high affinity second generation TSPO 
radioligand [18F]PBR111, in the same EAE mouse model [92]. 
Unlike the study performed by Mattner et al. [92] in which the uptake 
of the TSPO ligand [18F]PBR111 was evaluated at different stages of 
disease (pre-symptomatic, first episode, second episode), we focused 
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our study on the characterization of TSPO changes in symptomatic 
mice at the first episode thus including an higher number of mice that 
allowed to provide more robust results. Moreover using confocal 
imunofluorescence we were able to characterize the expression and 
the colocalization of TSPO and Iba1 staining in different brain regions 
and in the different tracts of spinal cord. The results of our 
immonofluorescence studies revealed increased expression of TSPO 
sites in the cervical, thoracic and lumbar tracts of the spinal cord that 
colocalized with strongly activated microglia cells. These findings are 
in line with those previously reported ex-vivo and in vivo with 
microPET and [18F]DPA-714 in rat MBP-EAE model [91]. We 
failed, as for SOD1 G93A mice, to detect in vivo in the spinal cord 
significant increase in [18F]DPA-714 uptake. Partial volume effects 
might have reduced the accuracy in mice due to the small size of 
spinal cord, as discussed for SOD1 G93A mice. In addition to the 
cerebellum, brainstem and the spinal cord, that showed an almost 
constant involvement, other regions were differently affected at 
individual level in our mice. In particular the thalamus, the 
hippocampus and the striatum revealed an increased [18F]DPA-714 
uptake at PET and a corresponding increased TSPO and iba1 
expression in post-mortem studies. These results underlie a certain 
heterogeneity of NI lesions, in line with a clinical heterogeneity. 
Future studies in a larger number of animals will allow to better 
characterize the other susceptible sites of NI in EAE-PLP in vivo and 
ex-vivo using TSPO markers.  
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5. Conclusions and future perspectives 
Overall, the results of the studies performed during this thesis suggest 
that TSPO sites are an interesting target for in vivo imaging of 
microglial activation in mice using microPET. Moreover, they 
highlight the feasibility of microPET studies and the relevant 
contribution of combined PET and immunohistochemistry for 
validation of new radioligands and for the characterization of cellular 
substrates underlying the in vivo PET signal in animal models of NI. 
Since PET provides also the possibility of measuring, in the same 
animal during the course of disease, the spatio-temporal dynamics of 
inflammatory cells or processes it is evident that this tool may 
contribute in the future to a better understanding of pathogenic 
mechanisms involved in animal models of NI, disease progression and 
therapeutic monitoring.  
More in particular, the aim of this thesis was to validate a recent 
fluorinated PET radioligand of TSPO sites, the [18F]DPA-714. The 
synthesis of this radiotracer has been implemented at the Department 
of Advanced Biomedical Sciences, University Federico II in 
collaboration with the Institute of Biostructure and Bioimaging (IBB)-
CNR and the PET studies were performed with the collaboration of 
IBB-CNR at Ceinge, Biotecnologie Avanzate thanks to the EU FP7 
grant n° HEALTH-F2-2011-278850 (INMiND o Imaging of 
Neuroinflammation in Neurodegenerative Diseases). 
In the first study, we have assessed the biodistribution and the 
specificity of [18F]DPA-714 in vivo in healthy mice. The results 
suggested that this radioligand has suitable characteristics for future in 
vivo studies with microPET in mice because it binds specifically to 
65 
 
TSPO sites, as indicated by the pattern of biodistribution and of the 
competitive inhibition, and it is not affected in vivo by the presence of 
significant radiometabolites during the time of PET studies.  
Based on these positive results in healthy mice we then assessed the 
feasibility and sensitivity of [18F]DPA-714 in mice models of NI, 
combining the ex-vivo validation with immunohistochemistry.  
We were the first to characterize in vivo with microPET and ex-vivo 
with immunolabeling the SNC patterns of microglial activation and 
TSPO expression in the ALS model SOD1 G93A. Despite some 
limitations that will be discussed below, our results demonstrated that 
increased TSPO expression in this mouse model could be detected in 
the brainstem and in the spinal cord and that it was related to 
increased microglial activation. Moreover, they highlight the specific 
neuroinflammatory involvement of brainstem nuclei and of the spinal 
cord in SOD1 familial form, a finding that open new perspectives in 
future in vivo studies of ALS patients using PET and TSPO 
radioligands. Interestingly, results obtained in a recent study using a 
multitracers PET approach, suggested that increased brain and spinal 
cord microglial activation measured with [11C]PK11195 in the same 
mouse model of ALS, might be associated with increased 
glutamatergic activity, measured with [18F]FPEB a specific mGluR5 
radioligand [86]. These findings have evident therapeutic 
implications. 
We also assessed in a third study the feasibility of microPET and 
[18F]DPA-714 in the study of microglial activation in the mouse 
model EAE-PLP. This is an acute form of MS mimicking the 
relapsing-remitting (RR) MS clinical form in humans. The 
preliminary results of these studies suggest that both brain and spinal 
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cord are site of increased TSPO expression in activated microglia as 
measured in vivo with PET and ex-vivo with immunohistochemistry. 
The severity of this inflammatory response seems to be related to the 
clinical score in the cerebellum and the brainstem, pointing out the 
susceptibility of these regions in this model and their role in disease 
severity.  
Overall, our results in NI mouse models suggest that micro-PET and 
[18F]DPA-714 might be a useful tool for the study of microglial 
activation in a model of NI related to neurodegeneration such as the 
G93A SOD1 and in a primary acute model of NI such as the EAE-
PLP. 
Nevertheless, some limitations have to be considered related to the 
methods and to the mice animal models. The first limitation is the low 
spatial resolution for detecting mild changes in small structures. We 
failed in both SOD1 and EAE-PLP mice to detect significant 
radioligand increase in the spinal cord despite the ex-vivo evidence of 
high increased microglial activation and TSPO expression in these 
regions.  Future studies should assess whether microPET with higher 
resolution, or the development of adequate methods for PVE 
correction, might improve the sensitivity and accuracy of the results in 
mice SNC models of NI. Overall, our results were obtained in a 
relative small number of mice, especially in the SOD1 model. Thus, 
further studies in a larger group of animals are needed to assess the 
sensitivity of [18F]DPA-714 PET in order to detect changes occurring 
in different regions of CNS of G93A SOD1 and EAE mice. Finally, 
preclinical results, although obtained in animal models showing 
neuropathological and clinical findings similar to those observed in 
humans, cannot be translated to human diseases. However they 
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represents an important tool for validation of new PET radioligands, 
characterization of the cellular substrates of in vivo PET signal, 
detections of PET longitudinal changes possibly including the 
presymptomatic stage and the evaluation of the effects of new 
therapeutic strategies.  
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6. Methods: radiochemistry, PET and 
immunohistochemistry  
 6.1. [18F]DPA-714 radiochemical synthesis 
All reagents and solvents were purchased from Sigma-Aldrich 
Corporation. DPA-714 (N,N-diethyl-2-(2-(4-(2-fluoroethoxy)phenyl)-
5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)acetamide) as reference 
compound and its tosyloxy derivative (toluene-4-sulphonicacid2-
[4(3diethylcarbamoylmethyl-5,7-dimethyl-pyrazolo[1,5-a]pyrimidin-
2-yl)-phenoxy]-ethyl-ester) as precursor for labeling with fluorine-18 
were resynthesized in our laboratories according to previously 
described procedures [96]. No-carrier-added fluorine-18 (half-life 
109.8 min) was produced via the [18O(p,n)18F] nuclear reaction by 
irradiation of a 2-mL [18O]water (97 % enriched; ABX, Radeberg, 
Germany) target on a General Electric MINItrace cyclotron (10 MeV 
proton beam), and the aqueous radioactive solution was then 
transferred to the appropriate hot cell. Target hardware consisted of a 
2-mL, two-port stainless steel target holder equipped with a domed-
end silver cylinder insert. The target to hot cell liquid-transfer system 
consisted of 33 meter tefzel tubing line (0.8 mm internal diameter; 
1/16-in external diameter), 2.0 bar helium drive pressure resulting in a 
transfer time of 1 minute. Typical production of 18F-fluorine at the 
end of a 25 μAh, 60-min (12.5 μAh) irradiation was 16 – 17 GBq (732 
– 769 mCi). 18F was then trapped in a Chromafix PS-HCO3 cartridge, 
and after elution with 0.550 mL K2CO3 (6 mg/mL) the 18F-fluorine 
was collected in a vessel containing Kryptofix-222 dissolved in 1 mL 
CH3CN (K222 15 mg/mL). [18F]DPA-714 was labeled with 18F-
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fluoride starting from the corresponding precursor using a tosyloxy-
for-fluorine nucleophilic aliphatic substitution according to previously 
described procedures with slight modification [96-97]. The specific 
activity at the end of synthesis and the radiochemical purity of 
[18F]DPA714 obtained within 90 min of radiosynthesis (HPLC 
purification and SepPak-based formulation included) were 300 
GBq/μmol and N>99 %, respectively. 
 
6.2. PET/CT 
All the studies were performed with small animal PET/CT scanner GE 
Healthcare eXplore Vista (Fig. 4), designed for mice and rats.  The 
main technical characteristics are as follows:  
PET → trans-axial FOV 6.7 cm, single axial FOV 4.8 cm, spatial 
resolution 1.8 mm FWHM/200 μm, sensitivity 4.2%  absolute central 
point-source sensitivity (ACS);  
CT → 200 μm CT resolution, 200 μA, 35 kVp, energy windows 250–
700 keV).  
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Fig 20. PET/CT scanner GE Healthcare eXplore Vista.  
 
 
After the radiotracer injection, dynamic and/or static images were 
acquired. All the acquired PET images were reconstructed using 2D 
FORE/3D OSEM iterative algorithm (voxel size 
0.3875×0.3875×0.775 mm) and corrected for random coincidences, 
scatter, physical decay to the time of injection.  
Counting rates were directly converted to Standardized Uptake Values 
(SUV = Tissue activity (MBq/cc)/ [Injected dose (MBq)/body weight 
(g)]) by use of a system calibration factor (1035 Bq/mL/cps/voxel) 
derived from the imaging of a mouse-size water-equivalent phantom 
containing fluorine-18.  
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6.3. Procedures and tissue processing for 
immunohistochemical studies and confocal acquisition in 
SOD1 and EAE mice 
 
Animals were deeply anaesthetized (isoflurane 4% and oxygen 
2L/min) and transcardially perfused. They received about 30 mL ice-
cold phosphate-buffered saline (0.1 M PBS), followed by about 60 mL 
of 4 % paraformaldehyde in saline solution. The brains and spinal 
cords were isolated, postfixed overnight at 4°C in 4% 
paraformaldehyde and cryoprotected in 30% sucrose in 0.1 M PBS for 
48h at 4°C. Sections were obtained using a sliding cryostat at 40 μm 
thickness. In collaboration with the Department of Neuroscience, 
Reproductive and Dentistry Sciences of University of Naples 
“Federico II”, free-floating sections were subjected to immunostaining 
and were incubated first with blocking solution (0.5% milk, 10% fetal 
bovine serum, 1 % bovine serum albumin) for 1.30h. Then, section 
were incubated overnight at 4°C with the following primary 
antibodies: rabbit monoclonal anti-PBR (1:500; Novus Biologicals) 
and mouse monoclonal anti-Iba1 (ionized calcium binding adapter 
molecule 1, 1:1000; Abcam). IBA1 is a 17-kDa EF hand protein that 
is specifically expressed in macrophages/microglia and is upregulated 
during the activation of these cells [98], following nerve injury, 
central nervous system ischemia, and several other brain diseases 
[99]. The sections were subsequently incubated with a cocktail of the 
corresponding fluorescent-labeled secondary antibodies (Alexa 
488/Alexa 594-conjugated antimouse/antirabbit IgGs).  
In double-labeled sections, the pattern of immunoreactivity for both 
antigens was identical to that seen in single-stained material. Control 
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double immunofluorescence staining entailed the replacement of the 
primary antisera with normal serum (data not shown). To minimize 
possible crossreactivity between IgGs in double immunolabeling 
experiments, the full complement of secondary antibodies was 
maintained, but the primary antisera were replaced with normal serum 
or only one primary antibody was applied (data not shown). In 
addition, the secondary antibodies were highly preadsorbed to the 
IgGs of numerous species. Tissue labeling without primary antibodies 
was also tested to exclude autofluorescence. No specific staining was 
observed under these control conditions, thus confirming the 
specificity of the immunosignals. 
Images were observed using a confocal microscope Zeiss LSM 700 
(Fig. 21). It is a four laser, point scanning confocal with a single 
pinhole and works together with ZEN software to obtain final images. 
Confocal microscopy is an optical imaging technique able to 
reconstruct a three-dimensional structure from sets of images obtained 
at different depths thanks to the use of a pinhole placed at the confocal 
plane of the lens to eliminate out-of-focus light. Fluorescence 
emission passing through the pinhole is reflected onto the diffraction 
grating surface using a dichromatic mirror. The spectrally separated 
light is then projected through the slit and into the photomultiplier.  
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Fig 21. Confocal microscope Zeiss LSM 700 
 
 
Single images were taken with an optical thickness of 0.7 μm at a 
resolution of 1024×1024 and 40× magnification.  
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